Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) Starts Presentation at LD Micro 2017 Invitational
Navidea Biopharmaceuticals (NYSE: NAVB) is a biopharmaceutical company that focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimer’s disease and mild cognitive impairment. It is also developing NAV5001, an Iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson’s disease and other movement disorders.…